References

aids

ВИЧ-инфекция и иммуносупрессии

HIV Infection and Immunosuppressive Disorders

2077-9828

Baltic Medical Education Center

10.22328/2077-9828-2021-13-3-81-95

aids-662

Research Article

ЛАБОРАТОРНАЯ ДИАГНОСТИКА

LABORATORY DIAGNOSTICS

Широко нейтрализующие антитела для лечения ВИЧ-инфекции

Broadly neutralizing antibodies for the treatment of HIV infection

https://orcid.org/0000-0001-6083-4478

Глазкова

Д. В.

Glazkova

D. V.

Глазкова Дина Викторовна — кандидат биологических наук, старший научный сотрудник

119121, Москва, Погодинская ул., д. 10, стр. 1

SPIN 4468–9003

Glazkova Dina Viktorovna

Moscow

georgin2702@gmail.com

https://orcid.org/0000-0003-3250-6498

Богословская

Е. В.

Bogoslovskaya

E. V.

Богословская Елена Владимировна — доктор медицинских наук, заведующий лабораторией разработки методов генной терапии

119121, Москва, Погодинская ул., д. 10, стр. 1

SPIN-код 4062–3678

Moscow

lenabo2@mail.ru

https://orcid.org/0000-0002-3668-6601

Шипулин

Г. А.

Shipulin

G. A.

Шипулин Герман Александрович — кандидат медицинских наук, заместитель директора по научно-производственной деятельности

119121, Москва, Погодинская ул., д. 10, стр. 1

SPIN-код 1908–9098

Moscow

shipgerman@gmail.com

https://orcid.org/0000-0002-7942-8004

Юдин

С. М.

Yudin

S. M.

Юдин Сергей Михайлович — доктор медицинских наук, профессор, генеральный директор

119121, Москва, Погодинская ул., д. 10, стр. 1

SPIN-код 9706–5936

Moscow

yudin@cspmz.ru

Центр стратегического планирования и управления медико-биологическими рисками здоровьюРоссияCentre for Strategic Planning and Management of Biomedical Health RisksRussian Federation

2021

24102021

1338195

2021

Глазкова Д.В., Богословская Е.В., Шипулин Г.А., Юдин С.М.

Glazkova D.V., Bogoslovskaya E.V., Shipulin G.A., Yudin S.M.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://hiv.bmoc-spb.ru/jour/article/view/662

Антитела, обладающие нейтрализующей активностью в отношении широкого спектра субтипов вируса иммунодефицита человека 1 (обозначаемые термином broadly neutralizing antibodies — bnAbs), представляют огромный интерес в качестве терапевтического агента для лечения ВИЧ-инфекции, поскольку при пассивной иммунизации они способны обеспечить защиту от большинства штаммов ВИЧ-1. В представленном обзоре обсуждаются механизмы формирования таких антител, их классификация по связыванию с консервативными областями оболочечного белка Env, а также присущие им особенности. Приведены данные по характеристикам наиболее перспективных для терапии bnAbs, а также их комбинаций.В последнем разделе рассмотрены уже имеющиеся на сегодняшний день результаты клинических испытаний широко нейтрализующих антител 3BNC117, VRC01 и 10-1074. При их анализе можно сделать важный вывод: введение только одного антитела сопровождается появлением резистентных вирусных вариантов. Результаты исследования единственной пока комбинации антител 3BNC117 и 10-1074 показывают, что такая терапия более эффективна и позволяет достичь длительной супрессии вируса у части пациентов. О перспективности комбинированной иммунотерапии ВИЧ свидетельствует инициация большого числа клинических испытаний комбинаций из двух или более широко нейтрализующих антител.

Antibodies with neutralizing activity against a wide range of human immunodeficiency virus 1 subtypes (known as broadly neutralizing antibodies — bNAb) are of great interest as a therapeutic agent for the treatment of HIV infection, because they are able to provide natural protection against most HIV-1 strains. The review discusses the mechanisms of formation of bNAbs, their classification by binding to conservative regions of the envelope protein, as well as their intrinsic features. Description of the most promising bNAbs and their combinations is presented.In the last section the results of clinical trials of 3BNC117, VRC01 and 10-1074 bNAbs available to date are reviewed in detail. An important finding of these studies was that the introduction of a single antibody is followed by the appearance of resistant viral variants. The investigation of the only combination of 3BNC117 and 10-1074 completed so far indicates that combined therapy is more effective and allows to achieve long-term viral suppression in some patients. The promise of combined HIV immunotherapy is evidenced by the initiation of a large number of clinical trials evaluating the efficacy of two or more different bNAbs.

ВИЧшироко нейтрализующие антителаклинические испытания

HIVbroadly neutralizing antibodies (bnAbs)clinical trials

References1

Wang Q. and Zhang L. Broadly neutralizing antibodies and vaccine design against HIV-1 infection // Front Med. 2020. Vol. 14, No. 1. Р. 30– 42. doi: 10.1007/s11684-019-0721-9.

Zhu P., Liu J., Bess J., Chertova E., Lifson J.D. et al. Distribution and three-dimensional structure of AIDS virus envelope spikes // Nature. 2006. Vol. 441, No. 7095. Р. 847–852. doi: 10.1038/nature04817.

Wyatt R., Sodroski J. The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens // Science. 1998. Vol. 280, No. 5371. Р. 1884– 1888. doi: 10.1126/science.280.5371.1884.

Stewart-Jones G.B.E., Soto C., Lemmin T., Chuang G.Y. et al. Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G // Cell. 2016. Vol. 165, No. 4. Р. 813–826. doi: 10.1016/j.cell.2016.04.010.

Walker L.M., Phogat S.K., Chan-Hui Po-Y., Wagner D. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV- 1 vaccine target // Science. 2009. Vol. 326, No. 5950. Р. 285–289. doi: 10.1126/science.1178746.

Alam S.M., McAdams M., Boren D., Rak M. et al. The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes. // J. Immunol. 2007. Vol. 178, No. 7. Р. 4424–4235. doi: 10.4049/jimmunol.178.7.4424.

Liao H.-X., Chen Xi, Munshaw S., Zhang R. et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated // J. Exp. Med. 2011. Vol. 208, No. 11. Р. 2237–2249. doi: 10.1084/jem.20110363.

Haynes B.F., Fleming J., Clair E.W.St. et al. Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies // Science. 2005. Vol. 308, No. 5730. Р. 1906–1908. doi: 10.1126/science.1111781.

Matyas G.R., Beck Z., Karasavvas N., Alving C.R. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV- 1 // Biochim. Biophys. Acta. 2009. Vol. 1788, No. 3. Р. 660–665. doi: 10.1016/j.bbamem.2008.11.015.

Barbas C.F. III, Björling E., Chiodi F., Dunlop N., Cababa D. et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro // Proc. Natl. Acad. Sci. USA. 1992. Vol. 89(19. Р. 9339–9343. doi: 10.1073/pnas.89.19.9339.

Burton D., Pyati J., Koduri R., Sharp S.J. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody // Science. 1994. Vol. 266, No. 5187. Р. 1024–1027. doi: 10.1126/science.7973652.

Gorny M.K., Conley A.J., Karwowska S., Buchbinder A., Xu J.Y., Emini E.A., Koenig S., Zolla-Pazner S. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody // J. Virol. 1992. Vol. 66, No. 12. P. 7538–7542. doi: 10.1128/JVI.66.12.7538-7542.1992.

Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Rüker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 // J. Virol. 1993. Vol. 67, No. 11. Р. 6642–6647. doi: 10.1128/JVI.67.11.6642-6647.1993.

Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., Katinger H. A Potent Cross-Clade Neutralizing Human Monoclonal Antibody against a Novel Epitope on gp41 of Human Immunodeficiency Virus Type 1 // AIDS Res. Hum. Retroviruses. 2001. Vol. 17, No. 18. Р. 1757–1765. doi: 10.1089/08892220152741450.

Zwick M.B., Labrijn A.F., Wang M., Spenlehaueret C. et al. Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 // J. Virol. 2001. Vol. 75, No. 22. Р. 10892–10905. doi: 10.1128/JVI.75.22.10892-10905.2001.

Wei X., Decker J.M., Wang S., Hui H. et al. Antibody neutralization and escape by HIV-1. // Nature. 2003. Vol. 422, No. 6929. Р. 307–312. doi: 10.1038/nature01470.

Richman D.D., Wrin T., Little S.J., Petropoulos C.J. et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection // Proc. Natl. Acad. Sci. USA. 2003. Vol. 100, No. 7. Р. 4144–4149. doi: 10.1073/pnas.0630530100.

Mascola J.R., Haynes B.F. HIV-1 neutralizing antibodies: understanding nature’s pathways. // Immunol. Rev. 2013. Vol. 254, No. 1. Р. 225– 244. doi: 10.1111/imr.12075.

Rusert P., Kouyos R.D., Kadelka C., Ebner H. et al. Determinants of HIV-1 broadly neutralizing antibody induction. // Nat. Med. 2016. Vol. 22, No. 11. Р. 1260–1267. doi: 10.1038/nm.4187.

Subbaraman H., Schanz M., Trkola A. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? // Retrovirology. 2018. Vol. 15, No. 1. Р. 52. doi: 10.1186/s12977-018-0433-2.

Dugast A.-S., Arnold K., Lofano G., Moore S. et al. Virus-driven Inflammation Is Associated with the Development of bNAbs in Spontaneous Controllers of HIV // Clin. Infect. Dis. 2017. Vol. 64, No. 8. Р. 1098–1104. doi: 10.1093/cid/cix057.

Aasa-Chapman M.M., Hayman A., Newton P., Cornforth D. et al. Development of the antibody response in acute HIV-1 infection // AIDS. 2004. Vol. 18, No. 3. Р. 371–381. doi: 10.1097/00002030–200402200–00002.

Mikell I., Sather D.N., Kalams S.A., Altfeld M., Alter G., Stamatatos L. et al. Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 // PLoS Pathog. 2011. Vol. 7, No. 1. Р. e1001251. doi: 10.1371/journal.ppat.1001251.

Landais E., Moore P.L. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. // Retrovirology. 2018. Vol. 15, No. 1. Р. 61. doi: 10.1186/s12977-018-0443-0.

Doria-Rose N.A., Schramm C.A., Gorman J., Moore P.L. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies // Nature. 2014. Vol. 509, No. 7498. Р. 55–62. doi: 10.1038/nature13036.

Klein F., Diskin R., Scheid J.F., Gaebler C. -et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization // Cell. 2013. Vol. 153, No. 1. Р. 126–138. doi: 10.1016/j.cell.2013.03.018.

Kepler T.B., Liao H.-X., Alam S.M., Bhaskarabhatla R. et al. Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies // Cell Host Microbe. 2014. Vol. 16, No. 3. Р. 304–313. doi: 10.1016/j.chom.2014.08.006.

Wardemann H., Yurasov S., Schaefer A., Young J.W., Meffre E., Nussenzweig M.C. Predominant Autoantibody Production by Early Human B Cell Precursors // Science. 2003. Vol. 301, No. 5638. Р. 1374–1377. doi: 10.1126/science.1086907.

Mouquet H., Scheid J.F., Zoller M.J., Krogsgaard M. et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation // Nature. 2010. Vol. 467, No. 7315. Р. 591–595. doi: 10.1038/nature09385.

Diskin R., Scheid J.F., Marcovecchio P.M. et al. Increasing the Potency and Breadth of an HIV Antibody by using Structure-Based Rational Design // Science. 2011. Vol. 334, No. 6060. Р. 1289–1293. doi: 10.1126/science.1213782.

Yang G., Holl TM., Liu Y., Li Y., Lu X. et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies // J. Exp. Med. 2013. Vol. 210, No. 2. Р. 241–256. doi: 10.1084/jem.20121977.

Scheid J.F., Mouquet H., Ueberheide B., Diskin R. et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding // Science. 2011. Vol. 333, No. 6049. Р. 1633–1637. doi: 10.1126/science.1207227.

Zhou P., Wang H., Fang M., Li Y. et al. Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies // PLOS Pathog. 2019. Vol. 15, No. 6. P. e1007819. doi: 10.1371/journal.ppat.1007819.

Asokan M., Rudicell R.S., Louder M., McKee K. et al. Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization // J. Virol. 2015. Vol. 89, No. 24. Р. 12501–12512. doi: 10.1128/JVI.02097-15.

Wagh K., Seaman M.S., Zingg M., Fitzsimons T. et al. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections // PLoS Pathog. 2018. Vol. 14, No. 3. e1006860. doi: 10.1371/journal.ppat.1006860.

Xu L., Pegu A., Rao E., Doria-Rose N. et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques // Science. 2017. Vol. 358, No. 6359. Р. 85–90. doi: 10.1126/science.aan8630.

Steinhardt J.J., Guenaga J., Turner H.L., McKee K. et al. Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity // Nat. Commun. 2018. Vol. 9, No. 1. Р. 877. doi: 10.1038/s41467-018-03335-4.

Ko S.-Y., Pegu A., Rudicell R.S., Yang Z.-y. et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection // Nature. 2014. Vol. 514, No. 7524. Р. 642–645. doi: 10.1038/nature13612.

Gaudinski M.R., Coates E.E., Houser K.V., Chen G.L. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults // PLoS Med. 2018. Vol. 15, No. 1. Р. e1002493. doi: 10.1371/journal.pmed.1002493.

Gautam R., Nishimura Y., Pegu A., Nason M.C. et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges // Nature. 2016. Vol. 533, No. 7601. Р. 105–109. doi: 10.1038/nature17677.

Simek M.D., Rida W., Priddy F.H., Pung P. et al. Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm. // J. Virol. 2009. Vol. 83, No. 14. Р. 7337–7348. doi: 10.1128/JVI.00110-09.

Binley J.M., Wrin T., Korber B., Zwick M.B. et al. Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies // J. Virol. 2004. Vol. 78, No. 23. Р. 13232–13252. doi: 10.1128/JVI.78.23.13232-13252.2004.

Babcook J.S., Leslie K.B., Olsen O.A., Salmon R.A., Schrader J.W. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities // Proc. Natl. Acad. Sci. 1996. Vol. 93, No. 15. Р. 7843–7848. doi: 10.1073/pnas.93.15.7843.

Tiller T., Meffre E., Yurasov S., Tsuiji M., Nussenzweig M.C., Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning // J. Immunol. Methods. 2008. Vol. 329, No. 1–2. Р. 112–124. doi: 10.1016/j.jim.2007.09.017.

West A.P., Scharf L., Scheid J.F., Klein F., Bjorkman P.J., Nussenzweig M.C. Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy // Cell. 2014. Vol. 156, No. 4. Р. 633–648. doi: 10.1016/j.cell.2014.01.052.

Wu X., Yang Z.Y., Li Y. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 // Science. 2010. Vol. 329, No. 5993. P. 856–861. doi: 10.1126/science.1187659.

Rudicell R.S., Kwon Y.D., Ko S.Y. et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo // J. Virol. 2014. Vol. 88 (21). P. 12669–12682. doi: 10.1128/JVI.02213–14.

Huang J., Kang B.H., Ishida E. et al. Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth // Immunity. 2016. Vol. 45, No. 5. P. 1108–1121. doi: 10.1016/j.immuni.2016.10.027.

Julg B., Pegu A., Abbink P. et al. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys // J. Virol. 2017. Vol. 91, No. 16. P. e00498–17. doi: 10.1128/JVI.00498-17.

Scheid J.F., Horwitz J.A., Bar-On Y. et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption // Nature. 2016. Vol. 535, No. 7613. P. 556–560. doi: 10.1038/nature18929.

Shingai M., Nishimura Y., Klein F. et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia // Nature. 2013. Vol. 503, No. 7475. P. 277–280. doi: 10.1038/nature12746.

Nishimura Y., Gautam R., Chun T.W. et al. Early antibody therapy can induce long-lasting immunity to SHIV // Nature. 2017. Vol. 543, No. 7646. P. 559–563. doi: 10.1038/nature21435.

Sajadi M.M., Dashti A., Rikhtegaran T.Z. et al. Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses // Cell. 2018. Vol. 173 (7). P. 1783–1795. doi: 10.1016/j.cell.2018.03.061.

Walker L.M., Huber M., Doores K.J. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies // Nature. 2011. Vol. 477, No. 7365. P. 466–470. doi: 10.1038/nature10373

Mouquet H., Scharf L., Euler Z. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies // Proc. Natl. Acad. Sci. USA. 2012. Vol. 109, No. 47. P. E3268-E3277. doi: 10.1073/pnas.1217207109.

Nishimura Y., Gautam R., Chun T.W. et al. Early antibody therapy can induce long-lasting immunity to SHIV // Nature. 2017. Vol. 543, No. 7646. P. 559–563. doi: 10.1038/nature21435.

Sanders R.W., Derking R., Cupo A. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies // PLoS Pathog. 2013. Vol. 9, No. 9. P. e1003618. doi: 10.1371/journal.ppat.1003618.

Doria-Rose N.A., Bhiman J.N., Roark R.S. et al. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency // J. Virol. 2015. Vol. 90, No. 1. P. 76–91. doi: 10.1128/JVI.01791-15.

Sok D., van Gils M.J., Pauthner M. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex // Proc. Natl. Acad. Sci. USA. 2014. Vol. 111, No. 49. P. 17624–17629. doi: 10.1073/pnas.1415789111.

Huang J., Ofek G., Laub L. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody // Nature. 2012. Vol. 491, No. 7424. P. 406–412. doi: 10.1038/nature11544.

Williams L.D., Ofek G., Schätzle S. et al. Potent and broad HIV-neutralizing antibodies in memory B cells and plasma // Sci. Immunol. 2017. Vol. 2, No. 7. P. eaal2200. doi: 10.1126/sciimmunol.aal2200.

Wagh K., Bhattacharya T., Williamson C. et al. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection // PLoS Pathog. 2016. Vol. 12, No. 3. P. e1005520. doi: 10.1371/journal.ppat.1005520.

Julg B., Liu P.T., Wagh K. et al. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail // Sci. Transl. Med. 2017. Vol. 9, No. 408. P. eaao4235. doi: 10.1126/scitranslmed.aao4235.

Pegu A., Hessell A.J., Mascola J.R., Haigwood N.L. Use of broadly neutralizing antibodies for HIV-1 prevention // Immunol. Rev. 2017. Vol. 275, No. 1. P. 296–312. doi: 10.1111/imr.12511.

Cavacini L.A., Samore M.H., Gambertoglio J. et al. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120 // AIDS Res. Hum. Retroviruses. 1998. Vol. 14, No. 7. P. 545–550. doi: 10.1089/aid.1998.14.545.

Caskey M., Klein F., Lorenzi J.C. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 // Nature. 2015. Vol. 522, No. 7557. P. 487–491. doi: 10.1038/nature14411.

Ledgerwood J.E., Coates E.E., Yamshchikov G. et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults // Clin. Exp. Immunol. 2015. Vol. 182 (3). P. 289–301. doi: 10.1111/cei.12692.

Caskey M., Schoofs T., Gruell H. et al. Antibody 10–1074 suppresses viremia in HIV-1-infected individuals // Nat. Med. 2017. Vol. 23, No. 2. P. 185–191. doi: 10.1038/nm.4268.

Lynch R.M., Boritz E., Coates E.E. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection // Sci. Transl. Med. 2015. Vol. 7, No. 319. P. 319ra206. doi: 10.1126/scitranslmed.aad5752.

Bar K.J., Sneller M.C., Harrison L.J. et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption // N. Engl. J. Med. 2016. Vol. 375, No. 21. P. 2037–2050. doi: 10.1056/NEJMoa1608243.

Mendoza P., Gruell H., Nogueira L. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression // Nature. 2018. Vol. 561, No. 7724. P. 479–484. doi: 10.1038/s41586-018-0531-2.

Niessl J., Baxter A.E., Mendoza P. et al. Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity // Nat. Med. 2020. Vol. 26, No. 2. P. 222–227. doi: 10.1038/s41591-019-0747-1.

Bar-On Y., Gruell H., Schoofs T. et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals // Nat. Med. 2018. Vol. 24, No. 11. P. 1701–1707. doi: 10.1038/s41591-018-0186-4.

Mahomed S., Garrett N., Karim Q.A. et al. Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07–523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial // BMJ Open. 2020. Vol. 10, No. 11. P. e042247. doi: 10.1136/bmjopen-2020-042247.

The authors declare that there are no conflicts of interest present.